Who are VEN combined with azacitidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ven-combined-with-azacitidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

VEN combined with azacitidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VEN combined with azacitidine (VEN combined with azacitidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent and histone deacetylase inhibitor. Area: Oncology.

phase 3 Hypomethylating agent and histone deacetylase inhibitor DNA methyltransferase and histone deacetylase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

VEN combined with azacitidine (VEN combined with azacitidine) — Nanfang Hospital, Southern Medical University. VEN combined with azacitidine works by inhibiting DNA methyltransferase and histone deacetylase, leading to epigenetic modifications that promote cell differentiation and apoptosis in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VEN combined with azacitidine TARGET	VEN combined with azacitidine	Nanfang Hospital, Southern Medical University	phase 3	Hypomethylating agent and histone deacetylase inhibitor	DNA methyltransferase and histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent and histone deacetylase inhibitor class)

Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VEN combined with azacitidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ven-combined-with-azacitidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab